VXRTのチャート
VXRTの企業情報
| symbol | VXRT |
|---|---|
| 会社名 | Vaxart Inc （アビラジェン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 バクサルト(Vaxart Inc.)（旧名：Aviragen Therapeutics Inc.）は感染症を治療するための直接作用型抗ウイルス薬の発見・開発に従事する。同社は治療の選択肢が限られるウイルス感染症に対処する臨床開発中の3種類の候補製品を有する。製品は第IIb相の酒精試験で評価されるヒト・ライノウイルス（HRV）感染症の中・重度の喘息患者のための経口治療薬のvapendavir、呼吸器合胞体ウイルス（RSV）感染の治療・予防のための第Ⅱ相開発における経口融合（F）タンパク質阻害剤であるBTA585、ヒトパピローマウイルス6型および11型に起因するコンジロームの第II相開発における局所抗ウィルス治療薬であるBTA074を含む。同社は前臨床RSV非融合阻害剤プログラムを有する。同社は感染症を予防・治療できる小分子化合物の発見と開発に研究と薬剤開発キャパシティを集中する。 アビラジェン・セラピュ―ティクスは米国のバイオ医薬品企業。呼吸関連のウイルス感染に対応する経口・小分子化合物に焦点を当て、インフルエンザの治療向けリレンザ（グラクソスミスクラインより販売）やイナビル（第一三共製薬より販売）を開発したほか、鼻炎の原因であるライノウイルスや、呼吸系発疹ウイルスの治療薬の開発にも従事。本社はジョ―ジア州。 Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. |
| 本社所在地 | 290 Utah Ave. Suite 200 South San Francisco CA 94080 USA |
| 代表者氏名 | Wouter Latour ワウターラトゥール |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-550-3500 |
| 設立年月日 | 25263 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 16人 |
| url | www.aviragentherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/vxrt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.26800 |
| 終値（lastsale） | 4.88 |
| 時価総額（marketcap） | 34849002.32 |
| 時価総額 | 時価総額（百万ドル） 26.80374 |
| 売上高 | 売上高（百万ドル） 2.95000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7.39874 |
| 当期純利益 | 当期純利益（百万ドル） -9.05600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Vaxart Inc revenues totaled $2.1M. Net loss applicable to common stockholders totaled to $6.9M. Results are not comparable due to year end change. |
VXRTのテクニカル分析
VXRTのニュース
Vaxart signs pact with hVIVO to help develop oral COVID-19 vaccine pill 2022/06/30 13:15:55 Seeking Alpha
Vaxart (VXRT) said on Thursday it had entered an agreement with hVIVO Services Limited, a subsidiary of London-based firm Open Orphan. Under the agreement, hVIVO will conduct a study…
Open Orphan’s hVIVO developing the world’s first Omicron human challenge model 2022/06/30 06:23:09 Directors Talk
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, is developing the world’s first Omicron human challenge model. hVIVO has signed an agreement with Vaxart Inc., (NASDAQ: VXRT) to develop the model […]
Open Orphan hVIVO to develop the world’s first Omicron human challenge model 2022/06/30 06:22:59 DirectorsTalk
Vaxart becomes the first client of the programme to test its oral COVID-19 vaccine candidate Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, is developing the world''s first Omicron human challenge model. hVIVO has signed an agreement with Vaxart Inc. , (NASDAQ: VXRT) to develop the model with the intent to conduct a subsequent Omicron human challenge study in 2023 to test the efficacy of Vaxart''s oral vaccine candidate, VXA-CoV2-1. To develop the model, hVIVO will manufacture a new SARS-CoV-2 (COVID-19) challenge agent based on the Omicron variant. The Good Manufacturing Practice compliant virus manufacturing activities will commence immediately and are expected to complete by Q4 2022. Following manufacture of the challenge agent, the Company intends to conduct a characterisation study.
Vaxart Inc. (VXRT): What Makes The Stock Attractive? 2022/06/29 11:30:00 Marketing Sentinel
Vaxart Inc. (NASDAQ:VXRT) has a beta value of 0.69 and has seen 1.93 million shares traded in the last trading session. The company, currently valued at $429.57M, closed the last trade at $3.48 per share which meant it lost -$0.17 on the day or -4.66% during that session. The VXRT stock price is -196.84% off … Vaxart Inc. (VXRT): What Makes The Stock Attractive? Read More »
Vaxart: A Unique Vaccine Concern (NASDAQ:VXRT) 2022/06/14 19:40:48 Seeking Alpha
Vaxart is developing several vaccine candidates targeting large potential markets via an oral pill that can be stored at room temperature. See more on VXRT here.
Vaxart Stock: Awaiting Platform Validation for the Bull-Case to Kick In 2022/03/07 19:34:39 TipRanks
Vaxart (VXRT) shot to prominence in the early days of the pandemic, as one of the small vaccine makers taking the fight to Covid-19. But that was a while ago
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform 2022/02/26 08:24:19 Seeking Alpha
Vaxart GAAP EPS of -$0.17 misses by $0.01, revenue of $0.07M misses by $0.11M 2022/02/24 22:30:34 Seeking Alpha
Vaxart press release (NASDAQ:VXRT): Q4 GAAP EPS of -$0.17 misses by $0.01.Revenue of $0.07M (-80.6% Y/Y) misses by $0.11M.
Vaxart shares fall following data on COVID vaccine 2022/02/24 14:20:44 Seeking Alpha
Shares of Vaxart (VXRT) are down 10% in premarket trading after releasing mid-stage data on its oral COVID-19 vaccine candidate.
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart 2022/02/17 15:07:07 Benzinga
Macy''s Inc (NYSE: M ) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors. Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), BioNTech SE - ADR (NASDAQ: BNTX ), Novavax, Inc. (NASDAQ: … Full story available on Benzinga.com
Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average of $7.62 2021/12/19 12:22:41 Dakota Financial News
Vaxart, Inc. (NASDAQ:VXRT)s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.62 and traded as low as $6.41. Vaxart shares last traded at $7.20, with a volume of 9,325,846 shares trading hands. A number of equities research analysts []
Vaxart Stock Crosses 2 Key Levels Friday: What''s Next? 2021/12/17 19:42:52 Business Insider Markets
Vaxart Inc. (NASDAQ: VXRT ) shares were trading higher Friday after the company plans to test the cross-reactivity of its…
Vaxart shares rise 8% on promise of oral COVID vaccine against Omicron 2021/12/17 19:27:11 Seeking Alpha
A Sharp Uptick in Infections Reignites Fears of New Restrictions 2021/12/17 14:00:00 Benzinga
NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. In the meantime, restrictions for private businesses have become more strict. Todos Medical Ltd. (OTC: TOMDF ), Pfizer Inc. (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Vaxart, Inc. (NASDAQ: VXRT ) As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.